Search

everythinglearnresearchcommunity

for

Search:↓

Lower CD200R1 on certain immune cells is linked to more severe rheumatoid arthritis and immune imbalance.

Key genes and pathways involved in thyroid eye disease were identified, aiding potential treatment and diagnosis.

Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.

Antroquinonol may help prevent skin depigmentation by suppressing certain immune cells.

Alopecia Areata is treated with drugs and therapies to reduce inflammation and immune response.

Behçet's Disease may be caused by genetic and environmental factors leading to abnormal immune responses, and stress management and new treatments could improve patient outcomes.

The cause of alopecia areata was unknown, and while various treatments existed, no best treatment was agreed upon.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

The complement system might be involved in the development of alopecia areata and could lead to new treatments.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

Animal models, especially mice, are essential for advancing hair loss research and treatment.

TRP channels in the skin are important for sensation and health, and targeting them could help treat skin disorders.

IL-17 and certain immune cells are linked to more severe alopecia areata.

PPAR-γ may be a key target for treating alopecia areata and other skin conditions.

Toxic Epidermal Necrolysis is a rare, serious skin condition that can affect anyone, is more common in women, and may be linked to genetics, with a 20% mortality rate mainly due to sepsis.

Oxidative stress may contribute to hair loss in alopecia areata and antioxidants could potentially help as a treatment.

Androgens play a complex role in skin conditions like acne and hair loss in women, and normal blood levels don't always show true androgen status.

A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.

The meeting focused on understanding, diagnosing, and finding treatments for irreversible hair loss diseases.

ULBP3 could be a marker for diagnosing alopecia areata incognita and may be linked to its cause and development.

New treatments for hair loss show promise but need more research to confirm safety and effectiveness.

A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.

Acne vulgaris is a common skin condition that can cause low self-esteem and depression, and early treatment is important to prevent scarring.

Oxidative stress plays a significant role in vitiligo, and both skin and non-skin cells may be involved.

The hair follicle infundibulum plays a key role in skin health and disease, and understanding it better could lead to new skin disease treatments.

Alopecia areata can be triggered by specific immune cells without genetic or environmental factors.

Androgens may influence T cells, contributing to higher autoimmune liver disease risk in women.

New vitiligo treatments focus on controlling immune damage and restoring skin color.

Algal oligosaccharides help prevent hair loss and promote hair growth.

ULBP3 levels are higher in Tinea capitis patients and may help predict the disease's severity.